Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen to acquire ophthalmology gene therapy play Nightstar
BioCentury
Mon, 03/4/19 - 10:37 am
Biogen
M&A
Nightstar Therapeutics
gene therapy
ophthalmology
New insight into how Biogen's Tecfidera works may lead to better MS therapies
Fierce Biotech
Sat, 03/2/19 - 12:49 pm
Biogen
Tecfidera
MS
multiple sclerois
R&D
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Mon, 02/25/19 - 12:24 pm
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
Mon, 02/25/19 - 10:16 am
Alkermes
Biogen
diroximel fumarate
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
Sun, 02/24/19 - 11:36 pm
M&A
Merck
Biogen
Biomarin
Eli Lilly
Bristol-Myers Squibb
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
Wed, 02/20/19 - 11:59 am
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Mylan takes step toward knocking down key patent for Biogen's top-seller
Biopharma Dive
Thu, 02/7/19 - 03:26 pm
Mylan
Biogen
Tecfidera
patents
inter partes review
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Fri, 02/1/19 - 10:36 pm
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test
Xconomy
Wed, 01/30/19 - 11:56 am
Roche
Alzheimer's disease
clinical trials
AC Immune
crenezumab
Biogen
aducanumab
Spinraza sales lift Biogen revenues
BioCentury
Tue, 01/29/19 - 11:15 pm
Biogen
earnings
aducanumab
Alzheimer's disease
Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs
Fierce Pharma
Sat, 01/12/19 - 11:37 am
JPMHC 2019
M&A
Pfizer
Biogen
Amarin
Biogen stock trends up on neurology disease deals
Biopharma Dive
Tue, 01/8/19 - 11:38 pm
Biogen
C4 Therapeutics
Skyhawk Therapeutics
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Mon, 01/7/19 - 11:20 am
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Six Things to Watch for at the JP Morgan Healthcare Conference
BioSpace
Fri, 01/4/19 - 10:35 am
Moderna Therapeutics
Sarepta Therapeutics
Biogen
Gilead Sciences
Bluebird Bio
Report: Pharma companies kick off new year with price hikes
Drug Delivery Business News
Wed, 01/2/19 - 10:11 am
Allergan
Bristol-Myers Squibb
Biogen
Pfizer
drug pricing
ICER says gene therapy may be more cost effective for spinal muscular atrophy
Yahoo/Reuters
Thu, 12/20/18 - 11:54 pm
Biogen
Spinraza
Novartis
spinal muscular atrophy
ICER
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Tue, 12/18/18 - 10:28 am
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Biogen backs away from AGTC after gene therapy failure
BioPharma Dive
Thu, 12/13/18 - 09:10 pm
gene therapy
Biogen
Applied Genetic Technologies
Biogen bails on AGTC after ocular gene therapy flunks trial
Fierce Biotech
Thu, 12/13/18 - 12:20 pm
Applied Genetic Technologies
gene therapy
Biogen
rAAV2tYF-CB-hRS1
Pages
« first
‹ previous
…
28
29
30
31
32
33
34
35
36
…
next ›
last »